{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=KYV-101",
    "query": {
      "intervention": "KYV-101"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T05:34:34.850Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06451159",
      "title": "A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Progressive Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "KYV-101 (Biological) - 0.33 ×10^8 cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "KYV-101 (Biological) - 1 ×10^8 cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Chemotherapy: cyclophosphamide (CYC)",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy: fludarabine (FLU)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bruce Cree",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "25 Years to 70 Years"
      },
      "enrollment_count": 10,
      "start_date": "2024-06-20",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-09-02T05:34:34.850Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06451159"
    },
    {
      "nct_id": "NCT06152172",
      "title": "CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Idiopathic Inflammatory Myopathies",
        "Diffuse Cutaneous Systemic Sclerosis",
        "SLE Nephritis",
        "ANCA Associated Vasculitis"
      ],
      "interventions": [
        {
          "name": "KYV-101",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David Porter",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2024-08-05",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-02-18",
      "last_synced_at": "2026-09-02T05:34:34.850Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06152172"
    },
    {
      "nct_id": "NCT06588491",
      "title": "KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stiff-Person Syndrome",
        "SPS"
      ],
      "interventions": [
        {
          "name": "Standard lymphodepletion regimen",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Kyverna Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 27,
      "start_date": "2024-09-25",
      "completion_date": "2026-06-25",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-09-02T05:34:34.850Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Rochester, Minnesota • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06588491"
    },
    {
      "nct_id": "NCT06384976",
      "title": "KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis, Primary Progressive",
        "Multiple Sclerosis, Secondary Progressive",
        "Multiple Sclerosis",
        "MS"
      ],
      "interventions": [
        {
          "name": "KYV-101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard lymphodepletion regimen",
          "type": "DRUG"
        },
        {
          "name": "Anti-CD20 mAB",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kyverna Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 120,
      "start_date": "2024-09-20",
      "completion_date": "2029-01",
      "has_results": false,
      "last_update_posted_date": "2025-01-13",
      "last_synced_at": "2026-09-02T05:34:34.850Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06384976"
    },
    {
      "nct_id": "NCT06298019",
      "title": "Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dermatomyositis"
      ],
      "interventions": [
        {
          "name": "KYV-101",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "72 Years",
        "sex": "ALL",
        "summary": "25 Years to 72 Years"
      },
      "enrollment_count": 21,
      "start_date": "2024-08-02",
      "completion_date": "2039-04",
      "has_results": false,
      "last_update_posted_date": "2025-05-21",
      "last_synced_at": "2026-09-02T05:34:34.850Z",
      "location_count": 2,
      "location_summary": "Palo Alto, California • Stanford, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06298019"
    },
    {
      "nct_id": "NCT06138132",
      "title": "A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Sclerosis",
        "Multiple Sclerosis, Primary Progressive",
        "Multiple Sclerosis, Secondary Progressive"
      ],
      "interventions": [
        {
          "name": "KYV-101 anti-CD19 CAR-T cell therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard lymphodepletion regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2024-04-10",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-09-02T05:34:34.850Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06138132"
    },
    {
      "nct_id": "NCT05938725",
      "title": "KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lupus Nephritis",
        "Lupus Nephritis - World Health Organization (WHO) Class III",
        "Lupus Nephritis - WHO Class IV"
      ],
      "interventions": [
        {
          "name": "KYV-101 anti-CD19 CAR-T cell therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard lymphodepletion regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kyverna Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2023-04-28",
      "completion_date": "2026-05-29",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-09-02T05:34:34.850Z",
      "location_count": 6,
      "location_summary": "Palo Alto, California • Denver, Colorado • Worcester, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Great Neck",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05938725"
    },
    {
      "nct_id": "NCT06193889",
      "title": "KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Myasthenia Gravis",
        "Generalized Myasthenia Gravis"
      ],
      "interventions": [
        {
          "name": "Standard of Care Treatment",
          "type": "DRUG"
        },
        {
          "name": "Standard lymphodepletion regimen",
          "type": "DRUG"
        },
        {
          "name": "KYV-101",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Kyverna Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 66,
      "start_date": "2024-08-28",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-09-02T05:34:34.850Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Orange, California • Palo Alto, California + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06193889"
    },
    {
      "nct_id": "NCT06400303",
      "title": "KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Systemic Sclerosis",
        "Systemic Sclerosis - Diffuse Cutaneous",
        "Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria"
      ],
      "interventions": [
        {
          "name": "KYV-101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard lymphodepletion regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kyverna Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2024-08-06",
      "completion_date": "2026-06-16",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-09-02T05:34:34.850Z",
      "location_count": 2,
      "location_summary": "Palo Alto, California • Great Neck, New York",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Great Neck",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06400303"
    },
    {
      "nct_id": "NCT07403188",
      "title": "A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Refractory Lupus Nephritis",
        "Myasthaenia Gravis",
        "Stiff Person Syndrome",
        "Rheumatoid Arthritis (RA)",
        "Multiple Sclerosis",
        "Dermatomyositis",
        "Systemic Sclerosis (SSc)"
      ],
      "interventions": [
        {
          "name": "KYV-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kyverna Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2025-11-24",
      "completion_date": "2041-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-11",
      "last_synced_at": "2026-09-02T05:34:34.850Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07403188"
    }
  ]
}